CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Principia Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Principia Biopharma Inc
220 East Grand Avenue
Phone: (650) 416-7700p:650 416-7700 South San Francisco, CA  94080  United States Fax: (302) 655-5049f:302 655-5049

This company was Merged or Acquired on 9/28/2020.
This company ceased filing statements with the SEC on 10/8/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Principia Biopharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies to patients with unmet medical needs in immunology and oncology. It uses its Tailored Covalency platform to design and develop reversible covalent and irreversible covalent, small molecule inhibitors. Its pipeline includes PRN1008, PRN1371 and PRN2246. PRN1008 drug candidate is designed for the treatment of chronic immunological disorders. PRN2246 is an irreversible covalent BTK inhibitor for the treatment of multiple sclerosis (MS), and other central nervous system (CNS) diseases. PRN1008 is also being developed for the treatment of multiple autoimmune diseases, such as pemphigus. PRN1371 is an inhibitor of Fibroblast Growth Factor Receptor (FGFR), designed for the treatment of solid tumors. The Company also focuses on developing oral immunoproteasome inhibitor for the treatment of inflammation and autoimmune disorders.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202012/31/2019YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Alan B.Colowick 57 4/1/2019
President, Chief Executive Officer, Director MartinBabler 55 4/22/2019 4/1/2011
Chief Financial Officer Christopher Y.Chai 54 12/1/2013 1/1/2013
10 additional Officers and Directors records available in full report.

Business Names
Business Name
Principia Biopharma Australia Pty Ltd.
PRNB

General Information
Number of Employees: 124 (As of 6/30/2020)
Outstanding Shares: 33,236,216 (As of 8/14/2020)
Shareholders: 28
Stock Exchange: NASD
Federal Tax Id: 263487603
Fax Number: (302) 655-5049
Email Address: info@principiabio.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023